	US 12,129,480 B2
	Targeted integration of nucleic acids
Chi Kin Domingos Ng, San Francisco, CA (US); Yongping Guo Crawford, Foster City, CA (US); Amy Shen, San Mateo, CA (US); Meixia Zhou, Foster City, CA (US); Bradley R. Snedecor, Portola Valley, CA (US); Shahram Misaghi, Oakland, CA (US); and Albert Eric Gao, San Mateo, CA (US)
Assigned to GENENTECH, INC., South San Francisco, CA (US)
Appl. No. 16/956,942
Filed by GENENTECH, INC., South San Francisco, CA (US)
PCT Filed Dec. 21, 2018, PCT No. PCT/US2018/067070 § 371(c)(1), (2) Date Jun. 22, 2020, PCT Pub. No. WO2019/126634, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/711,272, filed on Jul. 27, 2018.
Claims priority of provisional application 62/609,806, filed on Dec. 22, 2017.
Prior Publication US 2021/0002669 A1, Jan. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/90 (2006.01); C07K 16/00 (2006.01)

CPC C12N 15/907 (2013.01) [C07K 16/00 (2013.01); C12N 15/90 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C12N 2800/30 (2013.01); C12N 2800/90 (2013.01); C12N 2840/00 (2013.01)]

84 Claims

1. A targeted integration (TI) host cell comprising an exogenous nucleotide sequence integrated at an integration site within a specific locus of the genome of the host cell, wherein the locus is at least about 90% homologous to a sequence selected from: contig NW_006874047.1 (SEQ ID NO: 8); contig NW_006884592.1 (SEQ ID NO: 9), contig NW_006881296.1 (SEQ ID NO: 10), contig NW_003616412.1 (SEQ ID NO: 11), contig NW 003615063.1 (SEQ ID NO: 12), contig NW_006882936.1 (SEQ ID NO: 13), and contig NW_003615411.1 (SEQ ID NO: 14).